Drugs

Pompe Disease: FDA Approves Lumizyme

Comment count: 1

The Food and Drug Administration has OK'd the first U.S. treatment specifically for late-onset Pompe disease

posted on May 25, 2010 - 12:34pm

The U.S. Food and Drug Administration (FDA) has approved U.S. sales of the enzyme-replacement drug Lumizyme, the first treatment in the U.S. specifically for late-onset Pompe disease.

Lumizyme Now Commercially Available for Pompe

Comment count: 1

"Lumizyme has stopped the progression of my disease," says one of first to receive the drug since the FDA granted commercial approval

posted on June 21, 2010 - 4:25pm

Monique Griffin of Orlando, Fla., was one of the first in the nation to receive the commercially available treatment Lumizyme for acid maltase deficiency (AMD, or Pompe disease).

New DMD Care Recommendations

Comment count: 17

After a year of planning, new recommendations for physicians caring for DMD patients have been released

posted on December 3, 2009 - 4:23pm

A comprehensive set of clinical care recommendations for the diagnosis and management of Duchenne muscular dystrophy (DMD) is now available to medical professionals and families. The complete recommendations, in printable PDF format, can be read here:

Housing		Independence
Personal Stories		Psychological Factors
Service Animals		Safety
Legislation and Policy		Taxes

College And Beyond		Learning Disabilities
IEP and 504 Plans		MDA Summer Camps
Transition Programs

Diagnosis and Genetics		Drugs
Insurance and Costs		MDA Clinics
Medical Procedures		Exercise and Sports
Nutrition

Adolescents and Young Adults		Children with an MD
Parents with an MD		Siblings

Research Administration		Endocrine Myopathies
Metabolic Diseases of the Muscle		Motor Neuron
Muscular Dystrophies		Neuromuscular Junction
Other Myopathies		Research Updates
General Research		Diseases of the Peripheral Nerve
Inflammatory Myopathies		Clinical Trials and Studies